drugset
Drugs / MVA-MUC1-IL2
last change Oct 2011 re-read 2 minutes ago

MVA-MUC1-IL2

also known as TG4010

Vaccine

Developed for
cancer of unknown primary site · non-small cell lung carcinoma · prostate neoplasm
Investigated by
Transgene · Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI) · The Cleveland Clinic · University of Arizona · University of California, Los Angeles

Trials 3 · a red edge is where a trial was stopped

today NCT00415818 · Ph 2/3 NCT00040170 · Ph 2 NCT00004881 · Ph 1
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00004881 Apr 2000 → May 2004 cancer of unknown primary site Jonsson Comprehensive Cancer Center Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00040170 May 2002 → ? prostate neoplasm Transgene Terminated No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00415818 Dec 2005 → Mar 2010 non-small cell lung carcinoma Transgene Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as MVA-MUC1-IL2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040170 ↗
2

NCT00415818 ↗

NCT00004881 ↗
Known as TG4010 “TG4010 is a targeted immunotherapy based on a poxvirus (modified vaccinia virus Ankara) that codes for MUC1 tumour-associated antigen and interleukin 2.” PMID 22019520 ↗ Oct 2011
Modality Vaccine “MVA-MUC1-IL2 vaccine” NCT00004881 ↗
Route Subcutaneous “In the experimental arm patients receive subcutaneous injections of TG4010” NCT00415818 ↗